|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 将卒中纳入心血管风险预测工具美国心脏协会/美国卒中协会对医疗卫生专业人员的声明显示文摘背景和目的目前美国针对心血管事件风险预测以及一级和二级预防的指南声明均使用绝对风险估计值来识别血管事件高危患者以及可从特定干预措施中获益的患者。然而,这些指南并未明确地包括卒中患者。本指南对现有证据和争论进行概述以支持:(1)将卒中(尤其是动脉粥样硬化性卒中)患者纳入心血管病绝对风险增高的患者群体;(2)将卒中纳入血管性疾病风险预测工具的转归预测因素。方法和结果写作组成员由委员会联合主席基于先前在相关领域的研究成果来提名,并得到美国心脏协会(American Heart Association,AHA)卒中委员会科学声明监督委员会以及文稿监督委员会的批准。作者采用系统文献回顾(覆盖1980年1月至2010年3月期间的文献)并参考以往公布的指南、个人资料以及专家观点,以归纳现有证据,提出当前知识的不足,并根据AHA标准对适当的问题制定推荐意见。所有写作组成员均有机会对推荐意见进行评论并批准了最终版本。经广泛的AHA内部同行评议以及卒中委员会领导阶层和科学声明监督委员会的审阅后,最终获得AHA科学咨询和协调委员会的批准。将卒中患者(尤其是动脉粥样硬化性卒中患者)纳入冠状动脉和心血管病绝对高危人群的原因如下。首先,有证据显示,缺血性卒中患者发生致死性和非致死性心肌梗死或猝死的绝对风险增高,10年绝对风险≥20%,这一风险阈值已被一些指南用于定义冠状动脉疾病风险等危症。其次,纳入动脉粥样硬化性卒中的原因与纳入糖尿病、周围血管病、慢性肾脏病以及其他动脉粥样硬化性疾病的原因相同,尽管尚缺乏在所有人群或患者中风险增高的统一证据。再次,缺血性卒中的大动脉粥样硬化性卒中亚型与其他这些疾病的病理生理学机制相同。将卒中纳入高危因素将导致高危人群的数量扩大约10%。然而,由于卒中的异质性,尚不确定其他卒中亚型,包括出血性卒中以及非动脉粥样硬化性卒中亚型,是否应被视为具有相同水平的风险,因此有待进一步研究。鉴于卒中对残疾和死亡的影响、卒中与其他血管性疾病预防措施的相似性以及卒中在某些人群中较冠状动脉疾病更高的重要性,将卒中、心肌梗死和猝死纳入心血管事件风险预测工具的转归预测因素是合适的。美国以外的指南常常将卒中患者纳入心血管高危人群,并将卒中作为心脏终点的一个相关转归事件。结论动脉粥样硬化性卒中患者应被纳入会进一步发生冠状动脉粥样硬化事件的高危患者(10年≥20%)。是否应纳入非动脉粥样硬化卒中亚型尚不确定。对于一级预防,缺血性卒中应被纳入绝对风险评估方案的心血管疾病转归事件。将动脉粥样硬化性卒中作为一个高危因素或者更宽泛地将缺血性卒中视作一种转归事件纳入,可能对心血管病的预防具有重要意义,因为被评定为高危风险的患者数量将大幅增加。 | Daniel T. Lackland Mitchell S.V. Elkind Ralph D'Agostino Sr Mandip S. Dhamoon David C. Goff Jr Randall T. Higashida Leslie A. McClure Pamela H. Mitchell Ralph L. Sacco Cathy A. Sila Sidney C. Smith Jr David Tanne David L. Tirschwell Emmanuel Touze Lawrence R. Wechsler 4:~ 尤寿江(译) 于海龙(译) 刘慧慧(译) 张霞(译) 刘春风(译) | 2012 | 国际脑血管病杂志2012，20，11： | 13 |
| 2 | A model to predict survival in patients with end-stage liver disease显示文摘 | Patrick S. Kamath Russell H. Wiesner Michael Malinchoc Walter Kremers Terry M. Therneau Catherine L. Kosberg Gennaro D’Amico E.Rolland Dickson W.Ray Kim | 2001 | Hepatology2001，，2： | 10 |
| 3 | GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma显示文摘 | Jorge A. Marrero Patrick R. Romano Olga Nikolaeva Laura Steel Anand Mehta Claus J. Fimmel Mary Ann Comunale Anthony D’Amelio Anna S. Lok Timothy M. Block | 2005 | Journal of Hepatology2005，，6： | 5 |
| 4 | European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease显示文摘 | J.F. Rahier S. Ben-Horin Y. Chowers C. Conlon P. De Munter G. D’Haens E. Domènech R. Eliakim A. Eser J. Frater M. Gassull M. Giladi A. Kaser M. Lémann T. Moreels A. Moschen R. Pollok W. Reinisch M. Schunter E.F. Stange H. Tilg G. Van Assche N. Viget B. Vu | 2009 | Journal of Crohn’s and Colitis2009，，2： | 3 |
| 5 | The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery显示文摘 | K. S?ndenaa P. Quirke W. Hohenberger K. Sugihara H. Kobayashi H. Kessler G. Brown V. Tudyka A. D’Hoore R. H. Kennedy N. P. West S. H. Kim R. Heald K. E. Storli A. Nesbakken B. Moran | 2014 | International Journal of Colorectal Disease2014，，4： | 3 |
| 6 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management显示文摘 | A. Dignass G. Van Assche J.O. Lindsay M. Lémann J. S?derholm J.F. Colombel S. Danese A. D’Hoore M. Gassull F. Gomollón D.W. Hommes P. Michetti C. O’Morain T. ?resland A. Windsor E.F. Stange S.P.L. Travis | 2010 | Journal of Crohn’s and Colitis2010，，1： | 2 |
| 7 | Malignant Progression in IPMN: A Cohort Analysis of Patients Initially Selected for Resection or Observation显示文摘 | J. LaFemina N. Katabi D. Klimstra C. Correa-Gallego S. Gaujoux T. P. Kingham R. P. DeMatteo Y. Fong M. I. D’Angelica W. R. Jarnagin R. K. Do M. F. Brennan Peter J. Allen | 2013 | Annals of Surgical Oncology2013，，2： | 2 |
| 8 | 子宫内膜异位症妇女月经期腹膜及子宫内膜生物学相关细胞因子和生长因子的基因表达增加显示文摘Objective: To examine differential messenger RNA(mRNA)-expression of relevant cytokines, metalloproteases, growth and adhesion factors in endometrium and peritoneum from women with endometriosis when compared with women without the disease duringmenstrual and luteal phases of the cycle. Design: Patients with endometriosis were compared with control patients. Setting: University hospital. Patient(s): A total of 35 patients(20 patients during the luteal phase and 15 patients during the menstrual phase)were selected for this study on the basis of cycle phase and presence or absence of endometriosis. Intervention( s): In this study, endometriosis was laparoscopically and histologically confirmed in 24 women with endometriosis of revised American Society for Reproductive Medicine(ASRM) stage I-II(n=12) and revised ASRM stage III-IV(n=12), and the presence of a normal pelvis was documented by laparoscopy in 11 control patients. The macroscopically normal peritoneum tissues were collected from lateral wall left or right, near the colon ascendens or descendens. Main Outcome Measure(s): The expression levels were determined as ratios between the target molecules and β-actin as housekeeping gene. Result(s): In women with endometriosis, peritoneal mRNA levels of matrix metalloproteinase(MMP)-3, transforming growth factor-β, interleukin(IL)-6, and intercellular adhesion molecule-1 and endometrial mRNA levels of MMP-3, tumor necrosis factor(TNF)-α, and IL-8 were significantly higher during the menstrual phase when compared with luteal phase. During the menstrual phase of the cycle, both endometrial expression of TNF-α, IL-8, and MMP-3 mRNA levels and peritoneal expression of transforming growth factor-β, IL-6, and intercellular adhesion molecule-1 mRNA levels were significantly higher in women with endometriosis when compared with controls. Immunohistochemical staining confirmed the presence of TNF-αin peritoneum and endometrium in both women with endometriosis and controls. Conclusion(s): Increased endometrial and peritoneal cytokine mRNA expression during menstruation may contribute to a pelvic inflammatory microenvironment favoring the development of endometriosis. | Kyama C.M. Overbergh L. Debrock S. T.M. D'Hghe 党慧敏 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，10： | 2 |
| 9 | A model to predict survival in patients with end-stage liver disease显示文摘 | Patrick S. Kamath Russell H. Wiesner Michael Malinchoc Walter Kremers Terry M. Therneau Catherine L. Kosberg Gennaro D'Amico E.Rolland Dickson W.Ray Kim | 2001 | Hepatology2001，，2： | 2 |
| 10 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study显示文摘 | D. Hompes A. D’Hoore A. Wolthuis S. Fieuws B. Mirck S. Bruin V. Verwaal | 2014 | J. Surg. Oncol2014，，： | 2 |
| 11 | Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer显示文摘 | D. D’Ugo R. Persiani S. Rausei A. Biondi V. Vigorita S. Boccia R. Ricci | 2006 | European Journal of Surgical Oncology2006，，10： | 2 |
| 12 | Emergence of novel strains of avian infectious bronchitis virus in Sweden显示文摘 | Shahid Hussain Abro Lena H.M. Renstr?m Karin Ullman Mats Isaksson Siamak Zohari Désirée S. Jansson Sándor Belák Claudia Baule | 2011 | Veterinary Microbiology (-)2011，，2： | 2 |
| 13 | Immunogenicity of hepatitis B vaccine among hemodialysis patients: Effect of revaccination of non-responders and duration of protection显示文摘 | Sandra S. Chaves Danni Daniels Brian W. Cooper Susan Malo-Schlegel Susan MacArthur Karen C. Robbins John F. Kobetitsch Aimee McDaniel John F. D’Avella Miriam J. Alter | 2011 | Vaccine2011，，52： | 2 |
| 14 | 利用现场测试的加速度和速度数据确定位移的积分方法评价(英文)显示文摘目的:本文旨在研究不同波长载荷(包括车厢长度、构架长度以及轴距等)对位移确定的影响,利用积分方法确定位移的有效性和重复性的适用范围,以及研究列车速度和轴荷载对变形量的影响,为轨道基础位移监测提供重要的方法。创新点:1.评价和分析一种积分方法,该方法利用低通滤波法但不消除产生变形的主要频率;2.通过对位移、速度和加速度传感器在时域和频域结果的比较,使重复性得到保证。方法:利用线性可变差位移传感器、地震检波器以及加速度计获取轨道不同深度的位移、速度和加速度,然后利用巴特沃兹低通滤波器对3类数据进行滤波。通过对速度一阶积分、加速度二阶积分,获得由3种传感器测试得到的位移并验证其准确性。结论:通过测试和分析发现,95%的位移幅值来自于波长大于轴距(2.8 m)的激励,对应的低频为25 Hz(列车运行速度为200 km/h)。通过线性可变差位移传感器、地震检波器以及加速度计直接获得或间接积分获得的位移十分接近,验证了积分方法的有效性,且其具有较高的可重复性。 | F.LAMAS-LOPEZ Y.J.CUI S. COSTA D'AGUIAR N. CALON | 2017 | Journal of Zhejiang University-Science A(Applied Physics & Engineering)2017，18，7： | 2 |
| 15 | Spatial and temporal variation of historical anthropogenic NMVOCs emission inventories in China显示文摘 | Bo Y. Cai H. Xie S. D | 2008 | 2008 (149)2008，，149： | 2 |
| 16 | Future directions in inflammatory bowel disease management显示文摘 | Geert R. D’Haens R. Balfour Sartor Mark S. Silverberg Joel Petersson Paul Rutgeerts | 2014 | Journal of Crohn’s and Colitis2014，，： | 2 |
| 17 | General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study显示文摘 | Ralph B. D’Agostino Ramachandran S. Vasan Michael J. Pencina Philip A. Wolf Mark Cobain Joseph M. Massaro William B. Kannel | 2008 | Circulation2008，，6： | 2 |
| 18 | Vitamin D Deficiency and Risk of Cardiovascular Disease显示文摘 | Thomas J. Wang Michael J. Pencina Sarah L. Booth Paul F. Jacques Erik Ingelsson Katherine Lanier Emelia J. Benjamin Ralph B. D?Agostino Myles Wolf Ramachandran S. Vasan | 2008 | Circulation2008，，4： | 2 |
| 19 | Antithrombin III (ATILL) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study显示文摘 | F. Baudo T. M. Caimi F. deCataldo A. Ravizza S. Arlati G. Casella D. Carugo G. Palareti C. Legnani L. Ridolfi R. Rossi A. D’Angelo L. Crippa D. Giudici G. Gallioli A. Wolfler G. Calori | 1998 | Intensive Care Medicine1998，，4： | 2 |
| 20 | Perihepatic Lymph Node Micrometastases Impact Outcome after Partial Hepatectomy for Colorectal Metastases显示文摘 | Joseph J. Bennett MD Carl R. Schmidt MD David S. Klimstra MD Stephen R. Grobmyer MD Nicole M. Ishill MS Michael D'Angelica MD Ronald P. DeMatteo MD Yuman Fong MD Leslie H. Blumgart MD William R. Jarnagin MD | 2008 | Annals of Surgical Oncology2008，，4： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员